NEW YORK (GenomeWeb News) – The genetics research technology developer BioRealm has reeled in a $1 million grant from the National Institute on Drug Abuse to develop and launch a genotyping array aimed at supporting research projects focused on the genetics of nicotine dependency. 

The Phase II Small Business Innovation Research award will fund development of the Smokescreen array, which uses the Affymetrix Axiom technology to screen 600,000 genetic variants, the Monument, Colo.-based company said today. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.